Bharat Serums and Vaccines (BSVL), a biotech firm based in Mumbai, says it is now working to have more control over its supply chain, reduce import dependence and develop recombinant products in hormones. It is also eyeing acquisitions in South East Asia.
Recombinant products are made in the laboratory, and not from human blood or any human fluid. Thus, such manufacturing is insulated from global supply chain disruptions.
Speaking to Business Standard, BSVL MD and CEO Sanjeev Navangul said the firm is working on developing cell-lines, so that it can begin production of its hormone products with its own starting